Teva Pharmaceutical

Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The firm operates through following geographical segments: North America, Europe and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Teva Pharmaceutical reports robust Q4 earnings, eyes biosimilar growth

Teva Pharmaceutical's Q4 2022 performance showcased revenue growth, strong product momentum, and strategic initiatives in biosimilars and legal settlements. While challenges in debt reduction and market dynamics persist, the company's focus on growth opportunities and financial targets provides a positive outlook for stakeholders.

Teva Pharmaceutical reports revenue growth amidst biosimilar setbacks and opportunities

Teva's Q1 2023 showcased revenue growth, particularly in innovative products like AUSTEDO and AJOVY.
Despite challenges in the biosimilar pipeline and financial losses, the company remains focused on strategic initiatives.
Opportunities lie in UZEDY's market potential and capital allocation for growth and profitability.
Gross margin pressures and legal settlements add complexity to Teva's path forward, requiring careful management.

Teva Pharmaceutical reports Q2 growth, navigates challenges, eyes expansion

Teva Pharmaceutical's Q2 2023 earnings call highlighted revenue growth, operational strength, and commitment to ESG goals, despite facing GAAP losses and operational challenges.
With a focus on debt reduction, increased revenue outlook, and strategic opportunities in biosimilars and new markets, Teva aims to drive long-term growth and financial stability.
Analysts' questions on patient outreach, asset divestiture, and EU entry underscore areas for improvement, while progress on AUSTEDO and UZEDY reception signal positive momentum.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: North America, Europe, and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

A degree of uncertainty about the company's leadership compounded some rather discouraging recent developments.

Why Teva Stock Stumbled Again on Friday

TEVA reports dismal Q3 results, missing estimates for both earnings and sales. It slightly lowers its sales expectations for 2022 while keeping the adjusted earnings per share guidance intact.

TEVA Misses on Q3 Earnings, Cuts 2022 Sales View, Stock Down

There were two major developments with the company, both of which involved piles of money.

Why Teva Stock Sank On Thursday

Mr. Schultz said he won't renew his contract that expires in November 2023.

Teva Pharmaceutical to Replace CEO Kare Schultz

Teva Pharmaceutical Industries Limited (NYSE:TEVA ) Q3 2022 Earnings Conference Call November 3, 2022 8:00 AM ET Company Participants Ran Meir - Senior Vice President, Head of Investor Relations Kare Schultz - President and Chief Executive Officer Eli Kalif - Executive Vice President and Chief Financial Officer Sven Dethlefs - Executive Vice President, North America Commercial Conference Call Participants Elliot Wilbur - Raymond James Glen Santangelo - Jefferies Umer Raffat - Evercore Jason Gerberry - Bank of America Denis Reznik - BMO Capital Markets Ashwani Verma - UBS David Amsellem - Piper Sandler Operator Good day and thank you for standing by. Welcome to the Teva's Third Quarter 2022 Financial Results Conference Call.

Teva Pharmaceutical Industries Limited (TEVA) Q3 2022Earnings Call Transcript

The Israeli company will shell out as much as $4.2 billion nationwide as part of a tentative deal.

Teva Pharmaceuticals Will Pay Up To $523 Million In New York For Opioid Settlement

The New York Attorney General's office announced it has secured $523 million from Teva Pharmaceuticals and affiliates for its role in the opioid crisis, effectively marking the end of the state's litigation against opioid manufacturers and distributors not currently in bankruptcy proceedings.

New York Attorney General Letitia James secures $523 million from Teva Pharmaceuticals for role in opioid crisis

Teva Pharmaceutical Industries Ltd will pay up to $523 million to New York State as part of a nationwide settlement of lawsuits alleging the company helped fuel the U.S. opioid epidemic.

Teva to pay $523 mln to New York as it looks to move past opioid lawsuits

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd.

Teva Reports Third Quarter 2022 Financial Results

Clinics Across Florida, New Jersey & California Advancing Mental Health in Underserved Communities – Awarded Funding from Teva Pharmaceuticals, Direct Relief and NAFC

Teva Announces Results from 3-Year Study Assessing the Safety and Tolerability of AUSTEDO® (deutetrabenazine) Tablets for the Treatment of Chorea Associated with Huntington's Disease

The U.S. Food and Drug Administration said on Wednesday there was a shortage of Adderall, a treatment for attention deficit hyperactivity disorder, following intermittent manufacturing delays at Teva Pharmaceutical Industries Ltd.

U.S. FDA warns of ADHD drug Adderall shortage on Teva manufacturing delays

The European Commission's antitrust accusation against Teva is poorly timed. Teva's selling momentum could continue from here.

What To Do After EU Hits Teva With Antitrust Concerns

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), has reached an agreement with the Attorney General of Arkansas to settle the state's price-fixing claims against Teva. Under the terms of the settlement, Teva will pay the state $931,000, and the state will dismiss all of its claims against Teva and its affiliates once payment has been made. This is the fourth settlement of the price-fixing l

Teva Reaches Agreement With Arkansas to Settle the State's Price Fixing Claims

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its third quarter 2022 financial results on Thursday, November 3, 2022 at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of the call wil

Teva to Host Conference Call to Discuss Third Quarter 2022 Financial Results at 8 a.m. ET on November 3, 2022

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the initiation of a 3-year longitudinal registry and study to assess the impact of tardive dyskinesia (TD) and real-world treatment patterns and outcomes. The Phase 4, multicenter, prospective, observational two-part study is the largest-ever study of its kind for TD and will collect information from both patients and physicia

Teva Announces Largest-Ever Trial to Collect Information from Patients and Physicians About TD, its Impact and Progression Over Time, and Evaluate Treatment-Related Outcomes

The generic drugs specialist settled one of a number of state lawsuits over its business practices.

Why Teva Stock Shot More Than 3% Higher Today

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), has reached an agreement with the Attorney General (AG) of Georgia to settle the state's price-fixing claims against Teva. Teva will pay the state $3.346 million as part of the settlement, and the state will dismiss all of its claims against Teva and its affiliates once payment has been made. Teva is committed to doing business the right way,

Teva Reaches Agreement With Georgia to Settle the State's Price Fixing Claims

Teva is a solid company which faces/faced headwinds from their high debt load and opioid crisis settlement uncertainty. But with most of the settlement uncertainty behind them and their efforts to significantly lower their debt, their current valuation doesn't make sense.

Teva Pharmaceutical: Slow And Steady Road To A Higher Share Price

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the launch of the Honestly HD website, which aims to provide information, inspiration and resources to help people understand what to expect with Huntington's Disease (HD) chorea – one of the most visible and treatable symptoms of HD – and, how to talk to their doctor about preserving independence. In addition to the newly lau

Teva Launches Honestly HD Website to Provide People Living With Huntington's Disease (HD) Information, Inspiration and Resources on HD Chorea

Teva Pharmaceutical Industries expects to finalise an opioid settlement in the United States by year-end and start paying in 2023, its chief executive said on Sunday.

Teva Pharm expects to start paying U.S. opioid settlement in 2023 - CEO

The Zantac lawsuit will have minimal impact on Teva Pharmaceutical's financial position. At the end of August 2022, the company received approval in Europe for Ranivisio, which is a biosimilar of Lucentis, which is a medicine used to treat patients with certain.

Teva Pharmaceutical: Investment Opportunity During Fed Rate Hike

Teva Pharmaceutical's divestments have been many in recent years, and the company presents a different set-up than in the past. In about 5 years Teva Pharmaceutical has reduced its net debt by $14 billion, a remarkable sum for a company with a market cap of only $10 billion.

Teva Pharmaceutical: Past Behind And A Promising 2023

Dr. Reddy's Labs

Sol-Gel Technologies

The impact of COVID-19 and pricing pressure on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to TEVA, RDY and SLGL.

3 Generic Drug Stocks to Watch Amid Continued Pricing Pressure

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the first findings from the CONNECT clinical program on ProAir® Digihaler® (albuterol sulfate) inhalation powder with an integrated electronic module (eModule) will be presented at the European Respiratory Society (ERS) International Congress 2022, held September 4-6 in Barcelona, Spain. The CONNECT1 trial was c

Teva to Present First Data Set from the CONNECT1 Clinical Trial on ProAir® Digihaler® (albuterol sulfate) Inhalation Powder at the European Respiratory Society (ERS) International Congress 2022

News for Teva Pharmaceutical Stock (TEVA)